Drug firm Zydus Cadila on Monday said it had received final
approval from
the U.S. health regulator to market topiramate extended release
capsules, used
in the treatment of seizures and migraine. The company has
received approval
from the U.S. Food and Drug Administration to market the drug
in strengths
of 25 mg, 50 mg and 100 mg, Zydus Cadila said in a BSE filing.
Source: THE HINDU-28th November,2017
